Novel controlled-release polylactic-co-glycolic acid (PLGA) nanoparticles for sodium thiosulphate, a hydrogen sulphide donor, retains pro-angiogenic potential of hydrogen sulphide

Marwah, Mandeep; Shehzad, S.; Shokr, Hala; Sacharczuk, J.; Wang, Keqing; Ahmad, Shakil; Sanchez-Aranguren, Lissette

doi:10.1080/17458080.2022.2060963

Cited by 4 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro release of TRITC from PLGA/CS NPs was evaluated by modifying previously reported protocol. 41 Kinetic drug release mathematical models were used to assess drug release, and equations of kinetic models are shown in Table S1.…”

Section: = ×mentioning

confidence: 99%

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Payomhom,

Panyain,

Sakonsinsiri

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Ursolic acid (UA), a pentacyclic triterpenoid found in various fruits and herbs, has the potential as an anticancer agent against multiple cancer types. Nevertheless, its clinical use was limited by its poor water solubility. To overcome this drawback, several nanocarriers were proposed to increase the bioavailability and efficacy of UA. However, the insights into the cellular targets and mechanisms of UA and UA nanoparticles (NPs) remain limited. In this study, chitosan-coated poly(lactic-co-glycolic acid) (PLGA/CS) NPs were loaded with UA. The obtained (UA)-PLGA/CS NPs were spherical with an approximate size of 250 nm and an encapsulation efficiency of 25%. Owing to their promising potential as drug carriers, the NPs were successfully delivered into breast cancer cells (MCF-7 and MDA-MB-231). Moreover, (UA)-PLGA/CS NPs enhanced the anticancer activity of UA, as evidenced by the IC 50 values of 26.74 and 40.67 μM in MCF-7 and MDA-MB-231 cells, respectively. These values were lower than those of free UA (90.25 and 85.63 μM in MCF-7 and MDA-MB-231 cells, respectively). The improved cytotoxicity induced by (UA)-PLGA/CS NPs can be attributed to apoptosis induction, collective cell migration and invasion inhibition, and cell proliferation pathway disruption. These findings led to a better understanding of the anticancer effects and molecular mechanisms of (UA)-PLGA/CS NPs and their potential targets for breast cancer therapy.

show abstract

Section: = ×mentioning

confidence: 99%

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Payomhom,

Panyain,

Sakonsinsiri

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Furthermore, cationic liposomes used in the controlled release of H 2 S from sodium thiosulphate were able to retain its biological properties in hypoxia-like environment [ 110 ]. Finally, PLGA nanoparticles carrying sodium thiosulphate observed a sustained cellular drug uptake whilst maintaining the pro-angiogenic potential of H 2 S [ 109 ]. These new approaches are supported by other researchers exploring the use of mesoporous iron oxide nanoparticle (MION) with polyethylene glycol (PEG) and lactoferrin as carriers for the H 2 S donor DATS [ 111 ].…”

Section: Perspectives: Overcoming Limitations In H 2 ...mentioning

confidence: 99%

Hydrogen Sulphide-Based Therapeutics for Neurological Conditions: Perspectives and Challenges

et al. 2023

Self Cite

View full text Add to dashboard Cite

Central nervous system (CNS)-related conditions are currently the leading cause of disability worldwide, posing a significant burden to health systems, individuals and their families. Although the molecular mechanisms implicated in these disorders may be varied, neurological conditions have been increasingly associated with inflammation and/or impaired oxidative response leading to further neural cell damages. Therefore, therapeutic approaches targeting these defective molecular mechanisms have been vastly explored. Hydrogen sulphide (H2S) has emerged as a modulator of both inflammation and oxidative stress with a neuroprotective role, therefore, has gained interest in the treatment of neurological disorders. H2S, produced by endogenous sources, is maintained at low levels in the CNS. However, defects in the biosynthetic and catabolic routes for H2S metabolism have been identified in CNS-related disorders. Approaches to restore H2S availability using H2S-donating compounds have been recently explored in many models of neurological conditions. Nonetheless, we still need to elucidate the potential for these compounds not only to ameliorate defective biological routes, but also to better comprehend the implications on H2S delivery, dosage regimes and feasibility to successfully target CNS tissues. Here, we highlight the molecular mechanisms of H2S-dependent restoration of neurological functions in different models of CNS disease whilst summarising current administration approaches for these H2S-based compounds. We also address existing barriers in H2S donor delivery by showcasing current advances in mediating these constrains through novel biomaterial-based carriers for H2S donors.

show abstract

“…The H 2 S released from nanoparticles enhanced endothelial proliferation and tubular formation. In addition, the treated cells activated the ERK and p38 pathway, which plays a crucial role in angiogenesis via endothelial migration and proliferation …”

Section: Physiological Role Of H2s In Angiogenesismentioning

confidence: 99%

“…In addition, the treated cells activated the ERK and p38 pathway, which plays a crucial role in angiogenesis via endothelial migration and proliferation. 101 A H 2 S-based polylactic-co-glycolic acid microparticle system conjugated with donor DATS was developed to enhance angiogenesis in ischemic diseases. The H 2 S was released sustainably over a long period of time, leading to improved vascular branching in the HUVEC cells.…”

Section: H 2 S-based Biomaterials For Therapeutic Angiogenesis 341 Hy...mentioning

confidence: 99%

See 1 more Smart Citation

Gasotransmitter-Induced Therapeutic Angiogenesis: A Biomaterial Prospective

Becky

Sadhasivam

2022

ACS Omega

View full text Add to dashboard Cite

Gasotransmitters such as NO, H2S, and CO have emerged as key players in the regulation of various pathophysiological functions, prompting the development of gas therapy for various pathogeneses. Deficient production of gasotransmitters has been linked to various diseases such as hypertension, endothelial dysfunction, myocardial infarction, ischemia, and impaired wound healing, as they are involved in the regulatory action of angiogenesis. A better understanding of the regulatory mechanisms has given new hope to address the vascular impairment caused by the breakthroughs in gasotransmitters as therapeutics. However, the unstable nature and poor target specificity of gas donors limit the full efficacy of drugs. In this regard, biomaterials that possess excellent biocompatibility and porosity are ideal drug carriers to deliver the gas transmitters in a tunable manner for therapeutic angiogenesis. This review article provides a comprehensive discussion of biomaterial-based gasotransmitter delivery approaches for therapeutic angiogenesis. The critical role of gasotransmitters in modulating angiogenesis during tissue repair as well as their challenges and future directions are demonstrated.

show abstract

Novel controlled-release polylactic-co-glycolic acid (PLGA) nanoparticles for sodium thiosulphate, a hydrogen sulphide donor, retains pro-angiogenic potential of hydrogen sulphide

Cited by 4 publications

References 48 publications

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer Therapy

Hydrogen Sulphide-Based Therapeutics for Neurological Conditions: Perspectives and Challenges

Gasotransmitter-Induced Therapeutic Angiogenesis: A Biomaterial Prospective

Contact Info

Product

Resources

About